You just read:

AcelRx Pharmaceuticals Completes Patient Enrollment in Remaining Phase 3 Studies of ARX-04 as a Potential Treatment of Moderate-to-Severe Acute Pain

News provided by

AcelRx Pharmaceuticals, Inc.

Jun 28, 2016, 07:00 ET